Sysmex Europe

Press releases

Here you can find press releases on recent topics related to new product launches, technologies, services, partnerships and organisational changes in chronological order. All press releases are also available for download as PDF.

2020/12/23 | Kobe, Japan

Sysmex Obtains Marketing Approval for the HISCLTM IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in Novel Coronavirus (SARS-CoV-2)-Positive Patients

Target market: Japan
2020/12/03 | Kobe, Japan

Sysmex Launches Surgical Robot Unit, hinotoriTM Surgical Robot System

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that it will launch the hinotori Surgical Robot System, a surgical robot unit, and the HF Series Instrument, a reusable active endotherapy device (collectively referred to as "hinotori" hereinafter; manufacturer: Medicaroid Corporation [HQ: Kobe, Japan; President: Kaoru Asano]) on December 4, 2020 for medical institutions in Japan.
2020/11/09 | Kobe, Japan

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood - CTAD

The Content Presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2020/09/29 | Kobe, Japan

Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent

Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCLTM-5000 / HISCLTM-800
2020/08/11 | Kobe, Japan

Medicaroid receives Japanese regulatory approval for the “hinotori TM Surgical Robot System”, the first made-in-Japan robotic assisted surgery system

2020/08/11 | Kobe, Japan

Collaboration of Medicaroid, Kawasaki Heavy Industries and Sysmex for the business of the“hinotori TM Surgical Robot System”, a robotic assisted surgery system

2020/07/27 | Kobe, Japan

Sysmex Launches OncoGuideTM NET Expert Panel Support System in Cancer Genome Profiling

- Supporting the Establishment of a System for Efficient Cancer Genomic Medicine -
2020/07/27 | Kobe, Japan

Sysmex Launches Lab Assay Service for Research on Cytokines Related to the Novel Coronavirus (SARS-CoV-2)

- Aiming to Monitor the Risk of Increasing Severity and Treatment Effects in Clinical Applications-

Sysmex and OPTiM Jointly Establish New Company to Plan, Develop and Operate Medical AI and IoT Open Platforms and Digital Transformation Solutions

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and OPTiM Corporation (HQ: Minato-ku, Tokyo, Japan; President: Shunji Sugaya) jointly established and began conducting operations at D’PULA Medical Solutions Corporation on June 1, 2020. The company is in charge of planning, developing, and operating solution services that leverage open platforms and applications related to digital medicine.
2020/05/25 | Kobe, Japan

Sysmex Donates ¥30 Million to Kobe City Support Fund for Medical Professionals to Support COVID-19 Countermeasures

Our thoughts and prayers are with the families of those who have perished as a result of the novel coronavirus (COVID-19), and we offer our heartfelt sympathy to the patients currently suffering from this disease. We are truly grateful for the efforts of the medical community and all others who are working on the front lines to stop this pandemic from spreading. Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to donate ¥30 million to the Kobe City Support Fund for Medical Professionals to support measures for countering COVID-19.

Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy

Details of Report on Clinical Utility of OncoBEAM TM RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020)

Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business


Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland


Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31


Sysmex Wins Awards in 2019 Kinki Local Commendations for Innovations


Sysmex and OPTiM Reach a Basic Agreement on the Establishment of a Joint Venture to Accelerate the Commercialization of Digital Medicine to Support Next-Generation Healthcare and Diagnostics

Aiming toward the Early-Stage Provision of Platforms and Applications Related to Digital Medicine

Industry, Government and Academia Jointly Establish a General Incorporated Association to Promote the Bioresource Business

Jointly Established by Kobe University, the City of Kobe, the Foundation for Biomedical Research and Innovation at Kobe, and Sysmex

Knowledge Is Power - Celebrating 10 Years of Sysmex Academy and More


Sysmex Launches Caresphere™ QM, an Operational Support System for Testing Quality Management

Realizing the Operation of High-Quality Clinical Laboratories through our New Caresphere™ Solution

Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Fourth Consecutive Year


Japan’s First Automated Hematology Analyzer Registered by the National Museum of Nature and Science as “Essential Historical Material for Science and Technology”

-Using Unique Technology to Cultivate True Automation in Blood Cell Counting-

Liquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)


World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories

Contributing to Clean and Fair Sports Management by Enhancing the Quality of Doping Tests

Sysmex Inostics OncoBEAM™-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study


Sysmex Inostics’ SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM™ enhanced digital PCR technology for detection of mutations in circulating tumor DNA


Promoting Business Process Restructuring through Digitalization to Reinforce Corporate Foundations and Create New Value


Sysmex Opens Technopark East Site, a Bio-Diagnostic Reagent Base

Strengthening Diagnostic Reagent Functions through an Integrated Structure from the Development of Substances to the Development, Production and Distribution of Bio-Diagnostic Reagents

Sysmex Obtains CE Certification for Automated Hematology Analyzer XN-31, Which Has an Automatic Measurement Function for Red Blood Cells Infected by Malaria Parasites

Contributing to the Early Detection and Treatment of Malaria through Standardized and More Efficient Malaria Testing

Sysmex to Be Special Sponsor of the Kobe Marathon 2019

-We are pleased to have sponsored this exciting event since its inception in 2011-

With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement

-Aiming to Prevent Atherosclerosis-Related Diseases and Provide Treatment Opportunities-

Sysmex Launches Revohem FIX Chromogenic, a Blood Coagulation Factor IX Measurement Kit

-Japan’s First Coagulation Factor IX Measurement Kit Using Chromogenic Assay, Helping to Diagnose and Assist in the Treatment of Hemophilia B-

Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization

-To Accelerate Precision Medicine Through Globally Proven Experience-

CALiaGold – The new quantitative immunoassay from Sentinel Diagnostics for calprotectin measurement in SENTiFIT 270 Analyser


Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers


Strengthening Our Global R&D Structure to Foster Early-Stage Innovation


Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers


In vitro diagnostics company Sysmex Europe announces executive leadership change


Sysmex Inostics announces launch of OncoBEAM™ EGFR Kit v2 (RUO) in Europe and Asia


Sysmex, Toppan Printing, and RIKEN GENESIS Commence Launch of Fully Automated System (Research Use Only) to Detect Gene Mutations in Cancer Tissue

-Streamlining the Gene Testing Processes to Standardize the Testing-

Sysmex Partec’s CyFlow™ Counter System, a System to Test for CD4+ Lymphocytes, Receives WHO Prequalification

-Aiming to Help Improve the Quality of HIV Diagnosis and Treatment in Emerging Markets and Developing Countries-

Sysmex and JVCKENWOOD Jointly Establish Company to Use Micro and Nano-Fabrication Technology to Develop and Manufacture IVD Biodevices


Sysmex Establishes Subsidiary in Egypt and Begins Conducting Direct Sales and Services


Sysmex, the Foundation for Biomedical Research and Innovation at Kobe, and Kyoto University Begin Joint Research on Technologies for Diagnosing Immunological Diseases


Sysmex Launches New Products in Its System for the Testing of Cancer Lymph Node Metastasis Using the OSNA™ Method: Gene Amplification Detector RD-200 and LYNOAMP™ CK19

-Contributing to Standardization in the Testing of Cancer Lymph Node Metastasis by Shortening Testing Times and Augmenting Processing Capacity-

Sysmex Group Formulates New Long-Term Management Goals

Celebrating Our 50th Anniversary by Taking on New Challenges to Move to the Next Stage

Sysmex Announces “Sysmex Eco-Vision 2025”

—To contribute to a sustainable society—

Sysmex to Establish Bio-Diagnostic Reagent Center

Reinforcing Our Diagnostic Reagent Development and Production Function by Establishing a Location to Handle Integrated Development through Production and Distribution of Bio-Diagnostic Reagents

Sysmex Employee to Receive the “Medal with Purple Ribbon,” a Spring 2018 Medal of Honor


Sysmex to Launch JICA Project in the Republic of Ghana: "Collaboration Program for Disseminating Automated Urinalysis Diagnosis Technology”


Sysmex Europe GmbH to Transfer Management of All European Installations of The DigniCap Scalp Cooling System Back to Dignitana AB


Sysmex Launches Caresphere™, a New Network Solution

Supporting the Intelligent Use of Information for the Healthcare of the Future, Where the Use of Information is Accelerating

Advanced Medical Care Approval Received for Multiplex Gene Panel Testing to Advancing Personalized Medicine


Sysmex Formulates New Corporate Message:“Lighting the way with diagnostics”


Japan’s first-ever industry-academia alliance to realize the development of innovative medicine in Japan

Implementation of a one-stop bioresource project in Kyoto University, and the establishment of KBBM Co., Ltd. as a model of “industry-in-the-academia” industry-academia partnership

OncoBEAM™ RAS CRC liquid biopsy test now reimbursed in Germany by BARMER

Effective immediately, cancer patients insured by BARMER now have access to Sysmex’s OncoBEAM™ RAS CRC IVD test.

Sysmex to Be Special Sponsor of the Kobe Marathon 2018

-We are pleased to have sponsored this exciting event since its inception in 2011-

Sysmex Celebrates Its 50th Anniversary of Establishment

Gratitude for All the Support over the Past 50 Years and a Commitment to Continue Taking on Challenges toward the Advancement of Healthcare.

In depth: Performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS liquid biopsy testing for KRAS mutation detection presented at ASCO GI 2018


In depth: Performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS liquid biopsy testing for KRAS mutation detection presented at ASCO GI 2018


Liquid Biopsy performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS testing presented at ASCO GI 2018 meeting


Liquid Biopsy performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS testing presented at ASCO GI 2018 meeting

Copyright © Sysmex Europe GmbH. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.